CIM
LGND icon

CIM Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

CIM Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Buy
1,484
+49
+3% +$9.7K 0.08% 198
2025
Q4 		$271K Hold
1,435
– – 0.07% 192
2025
Q3 		$254K Buy
+1,435
New +$213K 0.07% 198
2022
Q1 		– Sell
-2,300
Closed -$222K – 277
2021
Q4 		$222K Buy
+2,300
New +$212K 0.07% 268
2021
Q3 		– Sell
-3,454
Closed -$283K – 315
2021
Q2 		$283K Buy
+3,454
New +$287K 0.09% 222
2021
Q1 		– Sell
-3,921
Closed -$243K – 312
2020
Q4 		$243K Hold
3,921
– – 0.08% 237
2020
Q3 		$233K Buy
3,921
+58
+2% +$3.96K 0.09% 214
2020
Q2 		$270K Buy
+3,863
New +$245K 0.11% 181
2020
Q1 		– Sell
-3,206
Closed -$209K – 220
2019
Q4 		$209K Sell
3,206
-2,509
-44% -$168K 0.08% 203
2019
Q3 		$355K Hold
5,715
– – 0.13% 192
2019
Q2 		$407K Sell
5,715
-112
-2% -$8.25K 0.15% 162
2019
Q1 		$457K Buy
5,827
+2,417
+71% +$183K 0.18% 143
2018
Q4 		$289K Buy
+3,410
New +$364K 0.13% 217
2017
Q4 		– Sell
-4,166
Closed -$354K – 331
2017
Q3 		$354K Sell
4,166
-4,174
-50% -$331K 0.13% 224
2017
Q2 		$632K Sell
8,340
-262
-3% -$18.3K 0.22% 111
2017
Q1 		$568K Hold
8,602
– – 0.2% 137
2016
Q4 		$545K Hold
8,602
– – 0.2% 143
2016
Q3 		$548K Buy
8,602
+337
+4% +$24.7K 0.21% 125
2016
Q2 		$615K Buy
+8,265
New +$613K 0.25% 111
2016
Q1 		– Sell
-4,894
Closed -$331K – 279
2015
Q4 		$331K Hold
4,894
– – 0.15% 160
2015
Q3 		$261K Buy
4,894
+585
+14% +$35.5K 0.13% 187
2015
Q2 		$271K Sell
4,309
-4,314
-50% -$235K 0.12% 182
2015
Q1 		$415K Hold
8,623
– – 0.18% 141
2014
Q4 		$286K Buy
8,623
+1,193
+16% +$38.8K 0.13% 167
2014
Q3 		$218K Buy
+7,430
New +$247K 0.11% 166

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

CIM Investment Management's LGND Position: Q1 2026 in Review

CIM Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 3.4% in Q1 2026, buying an estimated $9.7K and bringing the position to 1,484 shares worth $296K. The position accounts for 0.08% of the portfolio, ranked #198.

CIM Investment Management first reported a position in LGND in Q3 2014 and has held it in 25 quarters since. The position peaked at $632K in Q2 2017. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • CIM Investment Management held 1,484 shares of Ligand Pharmaceuticals worth $296K as of Q1 2026.
  • CIM Investment Management bought 49 Ligand Pharmaceuticals shares in Q1 2026, an estimated $9.7K.
  • Ligand Pharmaceuticals made up 0.08% of CIM Investment Management's portfolio in Q1 2026, its #198 holding.
  • CIM Investment Management first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 25 quarters since.
  • CIM Investment Management's Ligand Pharmaceuticals position peaked at $632K in Q2 2017.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.